BR0215717A - Carbon monoxide as a biomarker and therapeutic agent - Google Patents

Carbon monoxide as a biomarker and therapeutic agent

Info

Publication number
BR0215717A
BR0215717A BR0215717-9A BR0215717A BR0215717A BR 0215717 A BR0215717 A BR 0215717A BR 0215717 A BR0215717 A BR 0215717A BR 0215717 A BR0215717 A BR 0215717A
Authority
BR
Brazil
Prior art keywords
diseases
pulmonary
biomarker
therapeutic agent
carbon monoxide
Prior art date
Application number
BR0215717-9A
Other languages
Portuguese (pt)
Inventor
Augustine M K Choi
Leo E Otterbein
Original Assignee
Univ Yale
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale, Univ Johns Hopkins filed Critical Univ Yale
Publication of BR0215717A publication Critical patent/BR0215717A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

,"MONóXIDO DE CARBONO COMO UM BIOMARCADOR E AGENTE TERAPêUTICO". A presente invenção refere-se ao uso de monóxido de carbono (CO) como um biomarcador e agente terapêutico de coração, pulmão, fígado, baço, cérebro, pele e doenças do rim e outras condições e estados de doença incluindo, por exemplo, asma, enfisema, bronquite, síndrome de extenuação respiratória de adultos, sépses, fibrose cística, pneumonia, doenças intersticiais pulmonares, doenças idiopáticas pulmonares, outras doenças pulmonares incluindo hipertensão primária pulmonar, hipertensão pulmonar secundária, cânceres, incluindo de pulmão, laringe e de garganta, artrite, cura de feridas, doença de Parkinson, doença de Alzheimer, doenças vasculares periféricas e doenças trombóticas vasculares pulmonares, tal como embolia pulmonar. CO pode ser empregado para fornecer alívio antiinflamatório em pacientes sofrendo de condições de estresse oxidativo e outras condições, especialmente incluindo sépses e choque séptico. Além disso, monóxido de carbono pode ser usado como uma biomarca, ou agente terapêutico, para redução de síndromes respiratórias em pacientes com transplantes de pulmão, e para reduzir ou inibir o estresse oxidativo e inflamação em pacientes com transplantes., "CARBON MONOXIDE AS A BIOMARKER AND THERAPEUTIC AGENT". The present invention relates to the use of carbon monoxide (CO) as a biomarker and therapeutic agent for heart, lung, liver, spleen, brain, skin and kidney diseases and other disease conditions and conditions including, for example, asthma. , emphysema, bronchitis, adult respiratory distress syndrome, sepsis, cystic fibrosis, pneumonia, pulmonary interstitial diseases, idiopathic pulmonary diseases, other pulmonary diseases including primary pulmonary hypertension, secondary pulmonary hypertension, cancers including lung, larynx and throat, arthritis, wound healing, Parkinson's disease, Alzheimer's disease, peripheral vascular diseases, and pulmonary vascular thrombotic diseases, such as pulmonary embolism. CO can be employed to provide anti-inflammatory relief in patients suffering from oxidative stress conditions and other conditions, especially including sepsis and septic shock. In addition, carbon monoxide may be used as a biomarker or therapeutic agent for reducing respiratory syndromes in lung transplant patients, and for reducing or inhibiting oxidative stress and inflammation in transplant patients.

BR0215717-9A 2002-05-09 2002-05-09 Carbon monoxide as a biomarker and therapeutic agent BR0215717A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/014836 WO2003094932A1 (en) 2002-05-09 2002-05-09 Carbon monoxide as a biomarker and therapeutic agent

Publications (1)

Publication Number Publication Date
BR0215717A true BR0215717A (en) 2005-02-22

Family

ID=29418043

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215717-9A BR0215717A (en) 2002-05-09 2002-05-09 Carbon monoxide as a biomarker and therapeutic agent

Country Status (13)

Country Link
EP (1) EP1501523A4 (en)
JP (1) JP2005532314A (en)
KR (1) KR20040106515A (en)
CN (1) CN1638781A (en)
AU (1) AU2002308676B2 (en)
BR (1) BR0215717A (en)
CA (1) CA2484770A1 (en)
EA (1) EA200401478A1 (en)
MX (1) MXPA04011113A (en)
NO (1) NO20044865L (en)
RS (1) RS96904A (en)
UA (1) UA84402C2 (en)
WO (1) WO2003094932A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678390B2 (en) 1999-04-01 2010-03-16 Yale University Carbon monoxide as a biomarker and therapeutic agent
GB0111872D0 (en) 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
US7011854B2 (en) 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
CN100496509C (en) 2002-04-15 2009-06-10 联邦高等教育系统匹兹堡大学 Carbon monoxide product and its uses for treating ileus
EP1499328B1 (en) 2002-04-15 2015-09-16 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods of treating necrotizing enterocolitis
JP4549847B2 (en) * 2002-05-17 2010-09-22 イエール ユニバーシティ How to treat hepatitis
JP2005345242A (en) * 2004-06-02 2005-12-15 Tohoku Univ Evaluation method of chemotherapy medical treatment effect of lung cancer
JPWO2007073005A1 (en) * 2005-12-22 2009-06-04 学校法人慶應義塾 Methyl group transfer regulator
AU2007328549A1 (en) * 2006-12-06 2008-06-12 Alfama - Investigacao E Desenvolvimento De Produtos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
JP2010094122A (en) 2008-06-12 2010-04-30 Keio Gijuku Diagnosis-treatment option for head-and-neck tumor using micro-rna as biomarker
JP2012046470A (en) * 2010-08-30 2012-03-08 Japan Science & Technology Agency Enzyme activity inhibitor for gapdh
EP3583851A1 (en) * 2011-01-14 2019-12-25 Children's Hospital Los Angeles Solution of carbon monoxide for treatment of disease, including sickle cell disease
US8927750B2 (en) 2011-02-04 2015-01-06 Universitaet Zu Koeln Acyloxy- and phosphoryloxy-butadiene-Fe(CO)3 complexes as enzyme-triggered co-releasing molecules
US9365419B2 (en) 2011-03-24 2016-06-14 Technion Research & Development Foundation Ltd. Method of diagnosing, prognosing and monitoring alzheimer's disease
ES2656237T3 (en) 2011-04-19 2018-02-26 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
JP6134710B2 (en) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． Ruthenium monoxide releasing molecules and uses thereof
US10031126B2 (en) 2013-04-04 2018-07-24 The Regents Of The University Of California System and method for utilizing exhaled breath for monitoring inflammatory states
EP2868348A1 (en) * 2013-11-04 2015-05-06 Universität Zürich CO-releasing compounds & formulations thereof useful for inducing mitochondrial biogenesis and tissue repair
TW201618795A (en) * 2014-04-15 2016-06-01 波泰里斯股份有限公司 Systems and methods to improve organ function and organ transplant longevity
JP7161737B2 (en) * 2017-01-30 2022-10-27 哲也 石川 Methods for testing malignant tumors
EP3804731A4 (en) * 2018-06-08 2022-04-06 Sumitomo Seika Chemicals Co., Ltd. Composition for skin wounds
EP3804733A4 (en) 2018-06-08 2022-03-16 Sumitomo Seika Chemicals Co., Ltd. Composition for inflammatory gastrointestinal disorders
WO2020247825A1 (en) * 2019-06-06 2020-12-10 The General Hospital Corporation Carbon monoxide as a treatment for neurodegenerative disease
WO2022015986A1 (en) * 2020-07-16 2022-01-20 Cornell University Methods for treating metastatic cancer using low dose carbon monoxide
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5293875A (en) * 1992-06-16 1994-03-15 Natus Medical Incorporated In-vivo measurement of end-tidal carbon monoxide concentration apparatus and methods
DE4421433C1 (en) * 1994-06-18 1995-06-08 Lohmann Therapie Syst Lts Transdermal therapeutic system for treatment of, e.g., hypertension
PT921807E (en) * 1996-08-27 2004-04-30 Messer Griesheim Gmbh MEDICINES CONTAINING HYDROGEN
CN1507348A (en) * 2001-03-30 2004-06-23 ɣ����ҽҩ��˾ Carbon monoxide generating compounds for treatment of vascular, inflammatory and immune disorders

Also Published As

Publication number Publication date
AU2002308676B2 (en) 2009-06-11
CN1638781A (en) 2005-07-13
CA2484770A1 (en) 2003-11-20
EA200401478A1 (en) 2005-12-29
EP1501523A4 (en) 2006-12-13
AU2002308676A1 (en) 2003-11-11
EP1501523A1 (en) 2005-02-02
JP2005532314A (en) 2005-10-27
KR20040106515A (en) 2004-12-17
NO20044865L (en) 2004-12-07
RS96904A (en) 2007-02-05
MXPA04011113A (en) 2005-02-14
WO2003094932A1 (en) 2003-11-20
UA84402C2 (en) 2008-10-27

Similar Documents

Publication Publication Date Title
BR0215717A (en) Carbon monoxide as a biomarker and therapeutic agent
HUP0400659A2 (en) Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease
WO2003000241A3 (en) Novel pharmaceutical compositions based on anticholinergic agents, corticosteroids and betamimetic agents, for the treatment of inflammatory and/or obstructive respiratory tract diseases
MXPA04000793A (en) Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma.
NO20061254L (en) Pharmaceutical mixtures
WO2007109118A3 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
IL190835A0 (en) Sulfonamide derivatives, their preparation and use
AUPS057102A0 (en) Compositions and methods for treatment of skin disorders
MXPA03011702A (en) Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases.
AP1896A (en) The method of treating cancer
UA90287C2 (en) Sulfonyl amino cyclic derivatives and use thereof
BR0015270A (en) Method and compositions for treating lung diseases
WO2002083700A3 (en) Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
WO2006085226A3 (en) Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by insulin-like growth factor binding protein-3 (igfbp-3)
WO2004005341A3 (en) Full-length interferon gamma polypeptide variants
HK1036054A1 (en) Substituted beta-diketones and their use
HK1115132A1 (en) N-hydroxyamide derivatives and use thereof n-
WO2004045530A3 (en) Methods for treating, preventing, or reducing cardiac disorders using fadd inhibitors
IL180681A0 (en) Pyridine derivatives, their preparation and use
Kumar et al. A Rare Case of Chlorine Inhalation-induced Severe Acute Respiratory Distress Syndrome: A Case Report and Review of Literature
Venugopalan et al. Bronchorelaxing activity of lithium in vitro
Besutti et al. Emphysema is a marker of subclinical coronary artery disease in HIV infected patients
Wolter et al. Fumes in industrial fires can make inhalation injury more severe—a report of three cases of industrial burn accidents
Wedzicha Chronic obstructive pulmonary disease: acute exacerbations
Drury REMOTE EFFECTS OF SYPHILIS. BY HENRY C. DRURY, MD UNIV. DUBL.; FRCPI

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 33/00, A61K 33/08, A61P 11/00, A61P 17/02, A61P 19/02, A61P 25/16, A61P 25/28, A61P 29/00

Ipc: A61K 33/00 (2011.01), A61K 33/08 (2011.01), A61P 1

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained